Lead Product(s): Pimavanserin
Therapeutic Area: Psychiatry/Psychology Product Name: Nuplazid
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
The OLE study was designed to evaluate the long-term safety of NUPLAZID. All patients in the OLE were treated with NUPLAZID 34 mg. Of 459 patients enrolled in the OLE, 424 (92.4%) had a Week 4 efficacy assessment.